I. Statement of the Problem
The hepatitis A case definition is in need of revision to better align terminology across the acute viral hepatitides, improve the list of disease specific data elements and criteria for case ascertainment.

II. Background and Justification

Background
In 2006, 3,579 cases of acute Hepatitis A in the United States were reported to CDC; the overall incidence of reported acute Hepatitis A was 1.2 per 100,000 population, the lowest ever recorded. After asymptomatic infection and under-reporting are taken into account, an estimated 32,000 new infections occurred in 2006. Hepatitis A is characterized by the acute onset of illness with dark urine and jaundice. Prodromal symptoms may include fever, headache, malaise, anorexia, nausea, vomiting and diarrhea. A high percentage of infants and young children with hepatitis A infection will be asymptomatic or have non-specific symptoms, including diarrhea. Following the introduction of hepatitis A vaccine in 1995, the incidence of hepatitis A in the United States has fallen dramatically. The decline was accelerated by expanded vaccination recommendations in 1999 for the routine immunization of children living in states, counties, or communities in which Hepatitis A rates were consistently above the national average. In 2006, the vaccination recommendations were further expanded to include vaccination for children in all states. Hepatitis A is transmitted primarily by the fecal-oral route by either person-to-person contact or ingestion of contaminated food or water. Household contacts and sexual contacts of hepatitis A cases are at high risk of contracting hepatitis A and should receive post-exposure prophylaxis if previously unvaccinated. Foodborne outbreaks may occur as a result of infected food handlers with poor hygienic habits. Travelers from low endemic areas visiting countries where hepatitis A is highly endemic are at risk of contracting hepatitis A. Ongoing surveillance for hepatitis A is needed to monitor the effectiveness of current strategies in controlling disease.

Justification
Hepatitis A meets the following criteria for a nationally and standard notifiable condition, as specified in CSTE position statement 08-EC-02:
- A majority of state and territorial jurisdictions—or jurisdictions comprising a majority of the US population—have laws or regulations requiring standard reporting of Hepatitis A to public health authorities
- CDC requests standard notification of Hepatitis A to federal authorities
- CDC has condition-specific policies and practices concerning the agency’s response to, and use of, notifications.
III. Statement of the desired action(s) to be taken

CSTE requests that CDC adopt this standardized reporting definition for Hepatitis A to facilitate more timely, complete, and standardized local and national reporting of this condition.

IV. Goals of Surveillance

To provide information on the temporal, geographic, and demographic occurrence of Hepatitis A to facilitate its prevention and control.

V. Methods for Surveillance:

Surveillance for Hepatitis A should use the sources of data for case identification and the extent of coverage listed in Table V.

Table V. Recommended sources of data for case identification and extent of coverage for ascertaining cases of Hepatitis A.

<table>
<thead>
<tr>
<th>Source of data for case ascertainment</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Population-wide</td>
</tr>
<tr>
<td>clinician reporting</td>
<td>X</td>
</tr>
<tr>
<td>laboratory reporting</td>
<td>X</td>
</tr>
<tr>
<td>reporting by other entities (e.g., hospitals, veterinarians, pharmacies)</td>
<td>X</td>
</tr>
<tr>
<td>death certificates</td>
<td>X</td>
</tr>
<tr>
<td>hospital discharge or outpatient records</td>
<td>X</td>
</tr>
<tr>
<td>extracts from electronic medical records</td>
<td>X</td>
</tr>
<tr>
<td>telephone survey</td>
<td></td>
</tr>
<tr>
<td>school-based survey</td>
<td></td>
</tr>
<tr>
<td>other</td>
<td></td>
</tr>
</tbody>
</table>

VI. Criteria for case identification

A. Narrative: A description of suggested criteria for case ascertainment of hepatitis A.

Report any illness to public health authorities that meets any of the following criteria:

Clinical evidence: A person who is acutely ill with jaundice. Associated symptoms might include: fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, or abdominal pain.

AND/OR
Laboratory evidence: A person who has tested positive for IgM antibody to hepatitis A (IgM anti-HAV positive). A person with elevated serum aminotransferase levels (ALT or AST)\(^1\) who has tested positive for IgM antibody to hepatitis A.

Epidemiologic evidence: A person who meets either the clinical or laboratory criterion and is an epidemiologic contact, 15-50 days prior to onset of symptoms, of a laboratory-confirmed hepatitis A case.

Clinical data: A person whose healthcare record contains a diagnosis of hepatitis A.

Administrative data: A person whose death certificate lists hepatitis A as a cause of death or a significant condition contributing to death.

*Other recommended reporting procedures*
- All cases of Hepatitis A should be reported.
- Reporting should be on-going and routine.
- Frequency of reporting should follow the state health department’s routine schedule.

**B. Tables:**

**Table VI-B.** Table of criteria to determine whether a case should be reported to public health authorities. Requirements for reporting are established under State and Territorial laws and/or regulations and may differ from jurisdiction to jurisdiction. These criteria are suggested as a standard approach to identifying cases of this condition for purposes of reporting, but reporting should follow State and Territorial law/regulation if any conflicts occur between these criteria and those laws/regulations.

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Evidence</strong></td>
<td></td>
</tr>
<tr>
<td>Acute onset</td>
<td>N</td>
</tr>
<tr>
<td>Jaundice</td>
<td>N</td>
</tr>
<tr>
<td>Fever</td>
<td>O</td>
</tr>
<tr>
<td>Headache</td>
<td>O</td>
</tr>
<tr>
<td>Malaise</td>
<td>O</td>
</tr>
<tr>
<td>Anorexia</td>
<td>O</td>
</tr>
<tr>
<td>Nausea</td>
<td>O</td>
</tr>
<tr>
<td>Vomiting</td>
<td>O</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>O</td>
</tr>
</tbody>
</table>

\(^1\) Alanine aminotransferase (ALT), aspartate aminotransferase (AST)
<table>
<thead>
<tr>
<th>Abdominal Pain</th>
<th>O</th>
<th>O</th>
<th>O</th>
<th>O</th>
<th>O</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical and Administrative Data</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthcare record contains a diagnosis of hepatitis A</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death certificate lists hepatitis A as a cause of death or a significant condition contributing to death</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Laboratory Evidence</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elevated serum aminotransferase levels (ALT or AST)</td>
<td>N</td>
<td>N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A IgM positive</td>
<td>S</td>
<td>N</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Epidemiological Evidence</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact of a lab-confirmed Hepatitis A case 15-50 days prior to onset of symptoms</td>
<td>N</td>
<td>N</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
S = This criterion alone is sufficient to report a case
N = This criterion in conjunction with all other “N” and any “O” criteria in the same column is required to report a case.
O = At least one of these “O” criteria in each category in the same column (e.g., clinical presentation and laboratory findings)—in conjunction with all other “N” criteria in the same column—is required to report a case.

C. **Disease Specific Data Elements:**
Disease-specific data elements to be included in the initial report are listed below.

_Symptoms of viral hepatitis_

_Serum aminotransferase levels (ALT or AST)_

_Immunization History_
Number of doses of Hepatitis A vaccine received
Date of last dose

_Epidemiological Risk Factors_
_During the 2 to 6 weeks prior to the onset of symptoms did the patient:_
Have contact with a person diagnosed with Hepatitis A
Household contact (non-sexual)
Sexual contact
International Travel by patient or household contact
Countries visited
Attend or work in day care setting
Inject or use any “street” drugs
Patient History
The number of female sex partners
The number of male sex partners

Risk factors for Transmission
In the 2 weeks prior to or the 2 weeks after the patient had onset of symptoms, did the patient work as a food handler or personal care giver (nurse, patient aide)

VII. Case Definition for Case Classification

A. Narrative description of criteria to determine whether a case should be classified as confirmed:

Clinical case definition

An acute illness with a discrete onset of any sign or symptom consistent with acute viral hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain), and either a) jaundice, or b) elevated serum aminotransferase (ALT or AST\(^2\)) levels.

Laboratory criteria for diagnosis:

Immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) positive

Case classification

**Confirmed:** a case that meets the clinical case definition and is laboratory confirmed

or

a case that meets the clinical case definition and occurs in a person who has an epidemiologic link with a person who has laboratory-confirmed hepatitis A (i.e., household or sexual contact with an infected person during the 15-50 days before the onset of symptoms)

B. Classification Tables:

**Table VII-B.** Table of criteria to determine whether a case is classified.

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Case Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clinical Evidence</td>
</tr>
<tr>
<td>Acute onset</td>
<td>N</td>
</tr>
<tr>
<td>Jaundice</td>
<td>N</td>
</tr>
</tbody>
</table>

\(^2\) Alanine aminotransferase (ALT), aspartate aminotransferase (AST)
Fever | O | O | O | O
Headache | O | O | O | O
Malaise | O | O | O | O
Anorexia | O | O | O | O
Nausea | O | O | O | O
Vomiting | O | O | O | O
Diarrhea | O | O | O | O
Abdominal Pain | O | O | O | O

**Laboratory Evidence**

| Elevated serum aminotransferase levels (ALT or AST) | N | N
| Hepatitis A IgM positive | N | N

**Epidemiological Evidence**

| Household or sexual contact of a lab-confirmed Hepatitis A case 15-50 days prior to onset of symptoms | N | N

**Notes:**

N = This criterion in conjunction with all other “N” and any “O” criteria in the same column is required to classify a case.

O = At least one of these “O” criteria in each category in the same column (e.g., clinical presentation and laboratory findings)—in conjunction with all other “N” criteria in the same column—is required to classify a case.

**VIII. Period of Surveillance**

Surveillance should be on-going.

**IX. Data sharing/release and print criteria**

Notification to CDC for confirmed cases of Hepatitis A is recommended.

- All states receive a biannual reports of cases submitted for the year to date. In addition, reports of acute hepatitis A are summarized in the weekly MMWR and annually in the MMWR Summary of Notifiable Diseases. Also once a year, an extensive analysis of data is conducted for publication in a *Surveillance Summary* along with case reports of acute hepatitis B and C.
- At a minimum, all states receive a biannual report of cases, as well as the annual MMWR Summary of Notifiable Disease and *Surveillance Summary* for acute viral hepatitis.
- Publication of data will follow this schedule (at a minimum):
  - Weekly in the tables of notifiable diseases in the MMWR
  - Biannual feedback to state health departments
  - Annually in the MMWR annual Summary of Notifiable Diseases
  - Annually in a surveillance summary of acute viral hepatitis
There is no current plan to re-release case data. Aggregate reports are publicly available, and states maintain confidential surveillance databases.

X. References


XI. Coordination:

Agencies for Response:
(1) Thomas R Frieden, MD, MPH
   Director
   Centers for Disease Control and Prevention
   1600 Clifton Road, NE
   Atlanta GA 30333
   (404) 639-7000
   txf2@cdc.gov
XII. Submitting Author:
(1) Gary Heseltine MD MPH
   Epidemiologist
   Texas Dept. State Health Services
   Emerging and Infectious Disease Branch, MC 1960
   PO Box 149347
   Austin, TX 78714-9347
   Phone: 512-458-7111 ext. 6352
   gary.heseltine@dshs.state.tx.us

Co-Authors:
(1) Kristin Sweet, MPH
   Minnesota Department of Health
   Epidemiologist, Senior
   Immunization, Tuberculosis, and International Health Section
   625 North Robert Street
   St. Paul, MN 55155-2538
   (651) 201-4888
   kristin.sweet@state.mn.us